Bioconjugation Market Bioconjugation Market Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "Bioconjugation Market by Product ...

BofA Securities has recently resumed AbbVie Inc (ABBV) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 5, 2024, Daiwa Securities had reduced the ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $176.2 which represents a decrease of $-1.81 or -1.02% from the prior close of $178.01. The stock opened at $177.02 and touched a low of ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

The global antiviral drugs market is poised for consistent growth, projected to expand at a compound annual growth rate (CAGR ...

We recently compiled a list of the 10 Best Dividend Growth Stocks to Buy and Hold in 2025. In this article, we are going to ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a three-day winning streak.

Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Explore more ...

The Court issued a summary judgment decision granting Pfizer's motion that the '953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of ...